Home › Funds › WELCH & FORBES LLC › ABT

WELCH & FORBES LLC position in ABT

ABBOTT LABORATORIES · Health Care

WELCH & FORBES LLC reported holding 577,781 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$57.1M, representing 0.68% of its reported portfolio and ranking #40 among its reported holdings. WELCH & FORBES LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)577.78K sh
Reported value held$57.10M
Portfolio Weight0.68%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How WELCH & FORBES LLC's ABT position evolved

WELCH & FORBES LLC first disclosed a stake in ABT in Q3 2023 at 642,428 shares (US$62.2M). The position peaked in Q2 2025 at 634,135 shares, worth US$86.2M. Across 13 filings, WELCH & FORBES LLC increased the stake 1 time(s), trimmed it 4 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 577,781 shares valued at US$57.1M — a reduction of -17,348 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 642.43K $62.22M New
Q4 2023 638.66K $70.30M Reduce
Q1 2024 646.23K $73.45M Add
Q2 2024 645.51K $65.74M Hold
Q3 2024 639.11K $72.86M Reduce
Q4 2024 636.19K $71.96M Hold
Q1 2025 634.53K $84.17M Hold
Q2 2025 634.13K $86.25M Hold
Q3 2025 631.87K $84.63M Hold
Q4 2025 631.91K $79.17M Hold
Q1 2026 629.84K $64.67M Hold
Q2 2026 595.13K $54.00M Reduce
Q3 2026 577.78K $57.10M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has WELCH & FORBES LLC held ABT?

WELCH & FORBES LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is WELCH & FORBES LLC's current position in ABT?

As of Q3 2026, WELCH & FORBES LLC holds 577.78K shares of ABT (ABBOTT LABORATORIES), valued at $57.10M, representing 0.68% of its reported portfolio and ranking #40.

Has WELCH & FORBES LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), WELCH & FORBES LLC reduced its position in ABT. The position peaked in Q2 2025 at 634.13K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.